RxDoctor Payments Data

Daniel Chan, MD

Gastroenterology · Ewa Beach, HINPI 1255627980

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,443 of the $17,097 with a category attached, or 66.9%. 18 manufacturers reported payments, led by Pfizer at 57.4% of the total. Among gastroenterology clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,097in general payments, 2019–2025

Across 173 payments — averaging $98.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • Exact Sciences$4K
  • AbbVie$1K
  • Covidien LP$972
  • Takeda Pharmaceuticals U.S.A., Inc.$360
  • Sanofi$316
  • plus $1K from 12 others

What the payments were for

  • Speaking & faculty fees$11,44367%
  • Travel & lodging$1,3908%
  • Food & beverage$4,17924%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,097 in reported general payments places this provider in the 90th percentile of 71 gastroenterology providers in Hawaii.

See all gastroenterology providers in Hawaii

Medicare billing

Part B allowed, 2024
$55,226
Medicare patients
202
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide20$17,490
Mesalamine12$5,979
Omeprazole73$2,013
Pantoprazole Sodium120$1,857
Lubiprostone11$1,841
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl51$698
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl12$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,079$17,49020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 71 gastroenterology providers in Hawaii.

Other gastroenterology in Ewa Beach

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →